m+Medelevator.RU
← Поиск публикаций
International journal of general medicine · 2026

Post-Treatment Partial Pressure of Carbon Dioxide for Prognostic Stratification and Non-Invasive Ventilation Guidance in Elderly Patients with Community-Acquired Pneumonia and Heart Failure: The "Subgroup with Impaired Cardiac Response".

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Yang Congbin, Cao Xiaokun, Yang Hongmei, Lu Hu, Dong Hui, Yang Kai

Аннотация

BACKGROUND: Prognostic stratification in elderly patients with co-existing community-acquired pneumonia (CAP) and heart failure (HF) is challenging due to the limitations of static admission scores.

OBJECTIVE : To evaluate the prognostic value of the 72-hour post-admission partial pressure of carbon dioxide (PCO2_post) and its utility in guiding non-invasive ventilation (NIV) therapy.

METHODS: We analyzed 100 elderly patients with CAP and HF. Six-month mortality was the primary endpoint. Propensity score matching (PSM) was used to explore mechanistic differences between risk strata.

RESULTS: PCO2_post was a potent exploratory predictor of 6-month mortality (AUC=0.968), comparable to the Pneumonia Severity Index (AUC=0.960). A threshold of 47-48 mmHg stratified patients into two distinct risk groups (HR 23.55, P < 0.001). NIV significantly reduced HF events and accelerated symptom resolution only in the low-risk group (PCO2_post < 47mmHg). PSM analysis revealed that high-risk patients (PCO2_post mmHg ≥ 47) exhibited a "subgroup with impaired cardiac response", characterized by paradoxical BNP increases (median +1722.9 pg/mL), persistent inflammation (higher CRP), and slow clinical recovery.

CONCLUSION: PCO2_post is a pragmatic dynamic biomarker that identifies a specific subgroup with impaired cardiac response who derive limited benefit from NIV, suggesting the need for intensified clinical monitoring and consideration of alternative therapeutic approaches.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты